Eunyong Ahn
Research Subjects
Research Interests
Eunyong Ahn has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- TaeJin Ahn
Handong Global University
6 shared publications - Geum-Sook Hwang
Integrated Metabolomics Research Group, Metropolitan Seoul Center, Korea Basic Science Institute, Seoul, Republic of Korea
4 shared publications - Do Sik Min
College of Pharmacy, Yonsei University, Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea
3 shared publications - Enzhi Luo
Yonsei Institute of Pharmaceutical Sciences, College of Pharmacy, Yonsei University, Incheon 21983, South Korea
3 shared publications - Hee Chan Yoo
College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea
3 shared publications - Hee Seung Lee
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
3 shared publications
Latest Publications
- Open Access
- 7 March 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (2) , 302-319
Tumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation
Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome—within the circulating platelet population. Recent mechanistic evidence suggests that platelets can sequester extracellular DNA, including circulating tumor DNA (ctDNA), and may thereby act as a relatively protected, time‐integrated reservoir that extends the biological persistence of tumor‐derived fragments beyond the short plasma half‐life (tens of minutes to a few hours). This emerging platelet‐sequestered DNA (pDNA) signal complements more established platelet transcriptomic data; to date, most TEP‐based molecular profiling has relied on RNA and has shown promising performance in identifying diverse solid malignancies, including premalignant lesions, and in some settings facilitating localization of the tissue of origin. However, the translation of these findings into clinical‐grade assays is obstructed by substantial hurdles. Pre‐analytical inconsistencies (e.g., leukocyte/erythrocyte contamination, isolation protocol choice) introduce technical noise and pervasive batch effects that compromise reproducibility. These vulnerabilities have been underscored by failed external validations and poor generalizability of discovery‐phase classifiers in independent cohorts and prospective settings. This review critically dissects the factors influencing TEP diagnostic performance and outlines a concrete roadmap for clinical translation. We argue that rigorous standardization—universal standard operating procedures, harmonized pre‐analytics, and quantitative quality‐control metrics—is the sine qua non for implementation, to be followed by large‐scale, prospective validation trials designed to demonstrate clinical utility and by multi‐omics integration to maximize diagnostic yield.
- 7 March 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (2) , 302-319
Open AccessTumor‐educated platelets in cancer diagnostics and prognostics: A critical appraisal and roadmap for clinical translation
Tumor‐educated platelets (TEPs) are emerging as a compelling frontier in liquid biopsy, functioning as dynamic, systemic sensors that sequester and process tumor‐derived biomolecules. This interaction imprints an integrated molecular signature of malignancy—spanning the transcriptome, proteome, lipidome, and crucially, the captured genome—within the circulating platelet population. Recent mechanistic evidence suggests that platelets can sequester extracellular DNA, including circulating tumor DNA (ctDNA), and may thereby act as a relatively protected, time‐integrated reservoir that extends the biological persistence of tumor‐derived fragments beyond the short plasma half‐life (tens of minutes to a few hours). This emerging platelet‐sequestered DNA (pDNA) signal complements more established platelet transcriptomic data; to date, most TEP‐based molecular profiling has relied on RNA and has shown promising performance in identifying diverse solid malignancies, including premalignant lesions, and in some settings facilitating localization of the tissue of origin. However, the translation of these findings into clinical‐grade assays is obstructed by substantial hurdles. Pre‐analytical inconsistencies (e.g., leukocyte/erythrocyte contamination, isolation protocol choice) introduce technical noise and pervasive batch effects that compromise reproducibility. These vulnerabilities have been underscored by failed external validations and poor generalizability of discovery‐phase classifiers in independent cohorts and prospective settings. This review critically dissects the factors influencing TEP diagnostic performance and outlines a concrete roadmap for clinical translation. We argue that rigorous standardization—universal standard operating procedures, harmonized pre‐analytics, and quantitative quality‐control metrics—is the sine qua non for implementation, to be followed by large‐scale, prospective validation trials designed to demonstrate clinical utility and by multi‐omics integration to maximize diagnostic yield.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9, Figure S10, Figure S11 from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Supplementary Figures and Figure Legends for S1 to S11
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8, Figure S9, Figure S10, Figure S11 from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Supplementary Figures and Figure Legends for S1 to S11
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC.Significance:Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC.Significance:Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.
- Open Access
- 7 September 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (9) , e1774
Tailored chemotherapy: Innovative deep‐learning model customizing chemotherapy for high‐grade serous ovarian carcinoma
- 7 September 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (9) , e1774
Open AccessTailored chemotherapy: Innovative deep‐learning model customizing chemotherapy for high‐grade serous ovarian carcinoma
- 24 July 2023
- Published by Springer Nature in Nature Aging
- Vol. 3 (8) , 982-1000
Impaired BCAA catabolism in adipose tissues promotes age-associated metabolic derangement
Adipose tissues are central in controlling metabolic homeostasis and failure in their preservation is associated with age-related metabolic disorders. The exact role of mature adipocytes in this phenomenon remains elusive. Here we describe the role of adipose branched-chain amino acid (BCAA) catabolism in this process. We found that adipocyte-specific Crtc2 knockout protected mice from age-associated metabolic decline. Multiomics analysis revealed that BCAA catabolism was impaired in aged visceral adipose tissues, leading to the activation of mechanistic target of rapamycin complex (mTORC1) signaling and the resultant cellular senescence, which was restored by Crtc2 knockout in adipocytes. Using single-cell RNA sequencing analysis, we found that age-associated decline in adipogenic potential of visceral adipose tissues was reinstated by Crtc2 knockout, via the reduction of BCAA–mTORC1 senescence-associated secretory phenotype axis. Collectively, we propose that perturbation of BCAA catabolism by CRTC2 is critical in instigating age-associated remodeling of adipose tissue and the resultant metabolic decline in vivo.
- 24 July 2023
- Published by Springer Nature in Nature Aging
- Vol. 3 (8) , 982-1000
Impaired BCAA catabolism in adipose tissues promotes age-associated metabolic derangement
Adipose tissues are central in controlling metabolic homeostasis and failure in their preservation is associated with age-related metabolic disorders. The exact role of mature adipocytes in this phenomenon remains elusive. Here we describe the role of adipose branched-chain amino acid (BCAA) catabolism in this process. We found that adipocyte-specific Crtc2 knockout protected mice from age-associated metabolic decline. Multiomics analysis revealed that BCAA catabolism was impaired in aged visceral adipose tissues, leading to the activation of mechanistic target of rapamycin complex (mTORC1) signaling and the resultant cellular senescence, which was restored by Crtc2 knockout in adipocytes. Using single-cell RNA sequencing analysis, we found that age-associated decline in adipogenic potential of visceral adipose tissues was reinstated by Crtc2 knockout, via the reduction of BCAA–mTORC1 senescence-associated secretory phenotype axis. Collectively, we propose that perturbation of BCAA catabolism by CRTC2 is critical in instigating age-associated remodeling of adipose tissue and the resultant metabolic decline in vivo.
- 3 January 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (5) , 735-752
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC. Significance: Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.
- 3 January 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (5) , 735-752
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) exhibits severe hypoxia, which is associated with chemoresistance and worse patient outcome. It has been reported that hypoxia induces metabolic reprogramming in cancer cells. However, it is not well known whether metabolic reprogramming contributes to hypoxia. Here, we established that increased glutamine catabolism is a fundamental mechanism inducing hypoxia, and thus chemoresistance, in PDAC cells. An extracellular matrix component–based in vitro three-dimensional cell printing model with patient-derived PDAC cells that recapitulate the hypoxic status in PDAC tumors showed that chemoresistant PDAC cells exhibit markedly enhanced glutamine catabolism compared with chemoresponsive PDAC cells. The augmented glutamine metabolic flux increased the oxygen consumption rate via mitochondrial oxidative phosphorylation (OXPHOS), promoting hypoxia and hypoxia-induced chemoresistance. Targeting glutaminolysis relieved hypoxia and improved chemotherapy efficacy in vitro and in vivo. This work suggests that targeting the glutaminolysis–OXPHOS–hypoxia axis is a novel therapeutic target for treating patients with chemoresistant PDAC. Significance: Increased glutaminolysis induces hypoxia via oxidative phosphorylation-mediated oxygen consumption and drives chemoresistance in pancreatic cancer, revealing a potential therapeutic strategy of combining glutaminolysis inhibition and chemotherapy to overcome resistance.